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Abstract
Background: There is a growing interest in cord blood as a source of primitive stem cells with
the capacity for multilineage differentiation. Pure cell fractions are needed for the characterization
and in vitro expansion of stem cells as well as for their use in preclinical research. However,
enrichment of stem cells is challenging due to the lack of stem cell-specific markers and gentle
protocols for the isolation of highly pure stem cell fractions. Protocols developed for the
enrichment of peripheral blood-derived stem cells have been found to be suboptimal for cord
blood.
Results: In this study, immunomagnetic cell sorting protocols to purify CD34+, CD133+ and Lin-
cells from fresh and cryopreserved cord blood were optimized. Reproducible purities of up to 97%
were reached. The selected cells were highly viable having substantial colony-forming potential.
Conclusion: The optimized protocols enable rapid enrichment of highly pure hematopoietic stem
cells from both fresh and cryopreserved cord blood.
Background
Hematopoietic stem cells (HSC), with their unique self-
renewal and differentiation capacity, offer great potential
for the treatment of hematological disorders, immunode-
ficiency and inborn errors of metabolism [1,2]. HSCs can
be collected from mobilized peripheral blood (PB), bone
marrow (BM) and cord blood (CB). Lately, CB has been
increasingly utilized because it is readily available, HLA
mismatches are better tolerated and there is a decreased
risk of graft-versus-host disease when using CB-derived
HSCs when compared to the other sources [3]. Even
though the cell content of CB is limited, it has a higher fre-
quency of progenitor cells compared to PB or BM [3-5].
CB-derived CD34+ cells have also been shown to prolifer-
ate more rapidly than their counterparts from BM [6], and
CB-derived HSCs possess increased engraftment potential
when compared to cells from PB or BM [7,8]. In addition,
recent studies suggest that CB is a source of non-hemat-
opoietic stem or progenitor cells, such as mesenchymal
and endothelial precursors [9,10].
Enrichment of HSCs is based on the expression of certain
surface antigens or on the lack of expression of lineage-
specific antigens. The most commonly used surface
marker for HSC selection is the transmembrane glycopro-
tein CD34. CD34 is also used to quantify the stem cell
content of CB units banked for clinical use [11]. Most, if
not all, CD34+ cells express the CD133 glycoprotein on
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their surface. CD133 appears to be expressed on more
primitive cells and CD133+ cell grafts have been tested in
stem cell transplantation [12-14]. Alternative, but cur-
rently poorly characterized Lin- progenitor cells lack line-
age-specific markers [15,16]. Fluorescence-activated cell
sorting and immunomagnetic selection systems utilize
antibodies against these cell surface antigens to enrich
HSCs. However, the major challenge has been the diffi-
culty to produce highly pure HSC fractions from CB with
good recovery. Furthermore, the handling of CB is chal-
lenging due to the relatively high content of thrombocytes
and nucleated erythroid precursors which have a negative
impact on the mononuclear cell isolation. For these rea-
sons, standardized protocols for PB sample handling and
cell separation do not work well for CB. Only few studies
have investigated the efficiency of the immunomagnetic
selection method used to isolate CD34+ cells from CB.
Belvedere et al. compared the results from 49 selections
and reported mean CD34+ cell purities of 41% and 85%
after first and second passage through the separation col-
umn, respectively [17]. Melnik et al. report an average
purity of 60% for CB-derived CD34+ cells from 10 separa-
tions [18].
In this study, three different protocols were optimized to
enrich CD34+, CD133+ and Lin- HSCs with over 90%
purity from both fresh and cryopreserved CB. Cryopre-
served CB cells have been considered to be especially chal-
lenging in selection procedures because of cell aggregation
caused by cell damage during thawing. The used protocols
were based on positive selection of cells expressing CD34
and CD133, or on depletion of cells expressing lineage-
specific markers. The magnetic cell sorting system MACS
was used due to its gentleness and time-effectiveness. Fur-
ther, the clonogenic capacity of selected HSC populations
was determined using the colony-forming unit (CFU)
assay.
Results and discussion
Handling of CB cells
The isolation of pure mononuclear cell (MNC) fractions
from CB, and subpopulations thereof, brings about a spe-
cial challenge. This appears to be due to the large number
of thrombocytes and erythroid progenitors in CB. In the
Ficoll-Paque density gradient, all erythroid cells do not
necessarily sediment to the bottom layer, but are retained
in the interphase of plasma and Ficoll-Paque. The eryth-
roid cells remaining in the interphase are nucleated pro-
genitors that may hamper the subsequent
immunomagnetic selection of HSC populations. Treat-
ment with ammonium chloride or diethylene glycol may
be used to deplete red blood cells, but depletion was not
performed in this study as the nucleated erythroid progen-
itors are not easily lyzed and purities up to 97% were
reached without any additional treatment. The unusually
slow sedimentation of erythroid cells is not seen when
working with PB.
When handling cryopreserved CB cells, aggregation was
observed. Aggregation was reduced by replacing ethylene-
diamine tetraacetic acid (2 mM EDTA, Merck, Darmstadt,
Germany) with anticoagulant citrate dextrose solution,
formula A (0.6% ACD/A, Baxter Healthcare, Lessines, Bel-
gium) in the sample buffer. In some cases aggregation was
so substantial that the cells needed to be resuspended in
DNaseI containing buffer. DNaseI digests the DNA
released from dead cells and prevents aggregation. The
DNase treatment did not affect the viability or colony-
forming potential of selected CB cells. No cell aggregation
was seen when handling fresh CB cells.
MNC fraction
In cryopreserved CB, the mean MNC concentration was
5.14 × 109/l (range 0.96–10.00, SD = 3.43) (Figure 1), and
the mean platelet concentration was 8.30 × 109/l (range
0.00–17.00, SD = 5.46). Cryopreserved CB contained a
mean of 0.14 × 1012/l erythrocytes (range 0.02–0.67, SD
= 0.20), and the mean hematocrit was 2%.
Fresh CB contained a mean of 2.68 × 109/l MNCs (range
1.24–3.62, SD = 0.64) (Figure 1). The difference in MNC
concentration between cryopreserved and fresh samples
was not statistically significant (P = 0.06). The remarkably
high disparity in the standard deviation of MNC concen-
tration between cryopreserved and fresh CB may be due to
the processing and freezing of cells performed to bank the
Mean MNC count in cryopreserved and fresh CB Figure 1
Mean MNC count in cryopreserved and fresh CB. The 
mean MNC concentration for cryopreserved and fresh CB 
was 5.14 × 109/l (range 0.96–10.00, median 4.30, SD = 3.43) 
and 2.68 × 109/l (range 1.24–3.62, median 2.77, SD = 0.64), 
respectively. The difference between cryopreserved and 
fresh CB was not statistically significant (P = 0.06). Bars show 
means and error bars show standard deviations. Abbrevia-
tions: MNC, mononuclear cells; CB, cord blood.
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CB units [19]. The mean concentration was 205.89 × 109/
l (range 84.00–505.00, SD = 130.58) for platelets and
0.12 × 1012/l (range 0.03–0.50, SD = 0.14) for erythro-
cytes. The mean hematocrit was 1%.
Immunomagnetic separation of HSC populations
When using the Direct CD34 Progenitor Cell Isolation Kit
with single column separation and the labeling protocol
recommended by the manufacturer (Miltenyi Biotec, Ber-
gisch Gladbach, Germany), a purity of less than 50% was
reached for the CD34+ cells (Figure 2). To obtain highly
pure CD34+ cells, the immunomagnetic selection method
was optimized. Several washing steps (3–10) were tested
for single column separation. A purity of 80% was
achieved with extensive washing, but the yield was poor
(less than 50% of the expected yield). Two successive col-
umn separations resulted in 77% purity, but a great
number of CD34+ cells were still lost during the process
indicating a further need to optimize the protocol. An
additional labeling step between the two column separa-
tions increased the purity to >90% (results for a represent-
ative sample shown in figure 3) and resulted in an
acceptable yield as well. The optimized two-column
method with additional labeling proved reliable and was
applied to the separation of both CD34+ and CD133+
cells. The average yield of CD34+ and CD133+ cells from
one cord blood unit was 106 and 105, respectively. The
purity of positively selected CD34+/CD133+ cells was
reproducibly over 90% and their negative counterparts
were nearly 100% pure.
Generally, the recovery of CD34+ and CD133+ cells was
0.86% (range 0.56–1.45, SD = 0.36) and 0.21% (range
0.04–0.41, SD = 0.12), respectively. The recovery of
CD34+ cells was higher from fresh CB (0.97%) when
compared to cryopreserved CB (0.78%), although the dif-
ference was not statistically significant (P= 0.54). The
results are consistent with the study by Almici et al. show-
ing no significant difference in yield or in purity for fresh
CB CD34+ cells in comparison to crypreserved cells [20].
This was the case with CD133+ cells as well, the recovery
being 0.29% for fresh CB and 0.12% for cryopreserved CB
(P = 0.11). The purities were not affected by the initial per-
centage of HSC populations in CB. The results of the
purity assessment for representative samples of CD34+/-,
CD133+/- and Lin-/+ cells are shown in figure 4.
The magnetic sorting of Lin- cells was optimized to find
the optimum concentrations for antibodies and magnetic
colloids. Lin- cells were separated from the MNC fraction
with magnetic cell sorting and the purity of the enriched
cell fraction was analyzed by flow cytometry. The average
Purity assessment of the CD34+ cell fraction by flow cytometry Figure 2
Purity assessment of the CD34+ cell fraction by flow cytometry. The initial purity of CD34+ cells after separation 
through single column was 47.5%. The CD34- fraction was 99.4% pure. CD34+ and CD34- cell populations were defined by 
first gating on forward and side scatter properties excluding platelets and debris. Subsequent gates were set to exclude >99% 
of control cells labeled with isotype-specific antibody. Percentages indicating the purity of isolated cell fractions are shown for 
both plots. Abbreviations: SSC, side scatter; PE, phycoerythrin.
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yield of Lin- cells from one cord blood unit was 106. The
overall recovery of Lin- cells was 0.29% (range 0.13–0.70,
SD = 0.21), being higher in fresh CB samples (0.43%)
than in cryopreserved CB samples (0.16%). The difference
between fresh and cryopreserved samples was not statisti-
cally significant (P = 0.19). The mean purity of Lin- cell
population was 90% (range 82–98%, SD = 5.00) and it
did not differ between fresh and cryopreserved CB units.
To assess the effect of antibody concentration on the selec-
tion of Lin- cells, varying amounts of the antibody cocktail
(50–100  µl/ml) and magnetic colloids (30–60 µl/ml)
were tested. The concentration of antibodies and mag-
netic colloids did not affect the purity of Lin- cells based
on flow cytometric analysis.
All the optimized protocols are described in detail in fig-
ure 5. The operation time for the selection of CD34+/- and
CD133+/- cells using MiniMACS or MidiMACS is approx-
imately 1.5 hours. The operation time for isolation of Lin-
/+ cells is approximately 45 minutes. The selection can be
made more effective with the AutoMACS system devel-
oped for high-speed automated cell sorting. The opti-
mized protocols have been developed for enrichment of
CB HSCs for research purposes. However, the enrichment
of stem and progenitor cells is often necessary in clinical
settings. The selected HSCs are increasingly used in trans-
plantations and enrichment may be required for deple-
tion of contaminating mature cells or tumor cells.
Potentially, the methods described here could be applied
to clinical-grade selection using the CliniMACS System
that is CE-marked for clinical use in Europe.
With the optimized protocols, a purity of at least 90% was
achieved for CD34+, CD133+ and Lin- cells. Viability was
99% for all the selected cell types. This demonstrates that
the optimized protocols work well for HSC enrichment
from both fresh and cryopreserved CB. Fresh CB was eas-
ier to handle and the recovery of HSCs was higher from
fresh CB. Nonetheless, cryopreserved cord blood is almost
exclusively used in clinical settings. Therefore, if one
wishes to use selected HSCs, the cells should preferably be
isolated on fresh cord blood and cryopreserved after the
selection procedure to maximize the recovery of HSCs.
HSCs, enriched by the protocols described here, have
been used in gene expression studies with great reproduc-
ibility and consistency [21].
It has been suggested that the binding of an antibody to
the surface of a HSC may influence cell proliferation and
differentiation by activating intracellular signaling path-
ways [14]. An anti-CD34 antibody has been shown to
induce tyrosine phosphorylation in BM-derived CD34+
Purity assessment of CD34+ cell fraction after one or two column separations Figure 3
Purity assessment of CD34+ cell fraction after one or two column separations. A) The CD34+ cell fraction was 78% 
pure after the first column separation. B) A 92% pure CD34+ cell faction was obtained by an additional labeling step in connec-
tion with a second column separation. CD34+ cell populations were defined by first gating on forward and side scatter proper-
ties excluding platelets and debris. Subsequent gates were set to exclude >99% of control cells labeled with isotype-specific 
antibody. Percentages indicating the purity of isolated cell fractions are shown for both plots. Abbreviations: SSC, side scatter; 
PE, phycoerythrin.
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Purity assessment of CD34+/-, CD133+/- and Lin-/+ cell fractions Figure 4
Purity assessment of CD34+/-, CD133+/- and Lin-/+ cell fractions. A) Purities for CD34+ and CD34- cell factions were 
97.1% and 99.1%, respectively. B) Purities for CD133+ and CD133- fractions were 93.6% and 99.1%, respectively. C) Purities 
for Lin- and Lin+ cell factions were 97.0% and 99.5%, respectively. CD34+/-, CD133+/- cell populations were defined by first 
gating on forward and side scatter properties excluding platelets and debris. Subsequent gates were set to exclude >99% of 
control cells labeled with isotype-specific antibody. Percentages indicating the purity of isolated cell fractions are shown for 
both plots. Abbreviations: SSC, side scatter; IgG, immunoglobulin; PE, phycoerythrin.
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A chart of the optimized protocols to isolate CD34+/-, CD133+/- and Lin-/+ cells from cord blood Figure 5
A chart of the optimized protocols to isolate CD34+/-, CD133+/- and Lin-/+ cells from cord blood. Isolation of 
CD34/- and CD133+/- cells was performed using Direct CD34 Progenitor Cell Isolation Kit (#130-046-702, Miltenyi Biotec) 
and CD133 Cell Isolation Kit (#130-050-801, Miltenyi Biotec), respectively. Lin-/+ cells were isolated using StemSep Human 
Progenitor Enrichment Kit (#14056, StemCell Technologies). For all magnetic separations, MACS columns and separators 
(Miltenyi Biotech) were used. Abbreviations: MNC, mononuclear cells; Buffer, PBS pH 7.2 supplemented with 0.5% bovine 
serum albumin and 2 mM EDTA or 0.6% ACD/A.
MNC
1. labeling
Prepare cell suspension of 300 µl of Buffer per 108 MNCs
Add 100 µl FcR Blocking Reagent and 100 µl Microbeads per 108 MNCs
Incubate at 6°C for 30 min
Wash with 10 ml of Buffer 
Centrifuge for 10 min at 300xg at 20°C
Resuspend in 500 µl of Buffer per 108 MNCs  
1. magnetic separation
Choose column according to the number of MNCs
MS for < 2 x 108 MNCs / LS for 2 x 108 –2  x  1 0 9 MNCs 
Place column in the magnetic field of the MACS separator
Rinse column with Buffer
500 µl MS / 3 ml LS
Apply labeled cell suspension to the column
Collect flowthrough as the CD34-/CD133- cell fraction
Wash column with Buffer
4 x 500 µl MS / 4 x 3 ml LS
Remove column from magnetic field and place on a tube
Elute and collect CD34+/CD133+ cells with Buffer 
2 x 1 ml MS / 2 x 5 ml LS
(use the plunger supplied with the column on the second elution)
2. labeling
Centrifuge for 5 min at 300xg at 20°C 
Resuspend in 300 µl of Buffer
Add 25 µl FcR Blocking Reagent and 25 µl Microbeads
Incubate at 6°C for 15 min
Wash with 4 ml of Buffer 
Centrifuge for 5 min at 300xg at 20°C
Resuspend in 500 µl of Buffer
2. magnetic separation
Place MS column in the magnetic field of the MACS separator
Rinse column with 500 µl of Buffer
Apply labeled cell suspension to the column
Wash column with Buffer 4 x 500 µl
Remove column from magnetic field and place on a tube
Elute and collect CD34+/CD133+ cells with Buffer 2 x 500 µ µ µ µl
(use the plunger supplied with the column on the second elution)
Labeling
Prepare cell suspension of 1 ml of Buffer per 8 x 107 MNCs
Add 100 µl Progenitor Enrichment Cocktail
Incubate at RT for 15 min
Add 60 µl Magnetic Iron Particles 
Incubate at RT for 15 min
Magnetic separation
Place LD column in the magnetic field of the MACS separator
Rinse column with 2 ml of Buffer
Apply labeled cell suspension to the column
Collect flowthrough as the Lin- cell fraction
Wash column with Buffer 2 x 1 ml 
(collect in the same tube with flowthrough)
Remove column from magnetic field and place on a tube
Elute and collect Lin+ cells with Buffer 2 x 1 ml
(use the plunger supplied with the column on the second elution)
CD34+/- and CD133+/- cells Lin-/+ cellsBMC Cell Biology 2006, 7:30 http://www.biomedcentral.com/1471-2121/7/30
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cells [22]. However, Lin- cells are selected through nega-
tive depletion. Thus, neither antibody binding nor activa-
tion of signaling pathways is expected. Further studies on
the effect of the interaction between HSCs and the anti-
bodies used for their selection as well as the possible
impact of this contact on HSC quality are awaited.
Low number of HSCs in cord blood is a limitation for its
use. Ex vivo expansion of HSCs may be used to generate
the clinically relevant cell numbers needed for adult
patients. However, mature cells may develop during long-
term culture and result in a need for reselection of progen-
itor cells. The optimized protocols can be applied for
enrichment of stem and progenitor cells after ex vivo
expansion.
Colony forming unit assay
The CFU assay was used to measure the clonogenic capac-
ity of CD34+, CD133+ and Lin- cells as well as MNCs.
Total CFU (CFU-TOT) number was determined as the
sum of granulocyte-erythroid-macrophage-megakaryo-
cyte (CFU-GEMM), granulocyte-macrophage (CFU-GM),
erythroid (CFU-E) and burst-forming erythroid (BFU-E)
colonies. CFU-TOT counts were 84.5, 80.0, 57.3 and 0.5
per 1000 cells for CD34+, CD133+, Lin- and MNCs,
respectively. CD34- and CD133- cell populations have
shown very limited colony forming potential in our previ-
ous studies with CFU-TOT counts of 0.1 and 0.6 per 1000
cells, respectively.
CFU-GM colonies (mean 53.2%) and CFU-GEMM colo-
nies (mean 32.6%) were the most common colony types
formed by of CB-derived HSCs. The proportion of differ-
ent colony types for CD34+, CD133+, Lin- and MNCs is
shown in Table 1. BFU-Es represented a mean of 12.9% of
the colony content of HSCs. However, the Lin- cell frac-
tion formed a surprisingly large number of BFU-Es
(27.3%), probably due to the inefficient removal of eryth-
roid progenitors during the depletion procedure. Very lit-
tle CFU-E colonies were observed (mean 1.3%), MNC
population being the most efficient in forming them
(5.5%). The high proportion of BFU-E and CFU-E colo-
nies formed by the MNC population reflects the unusual
sedimentation of erythroid progenitors in Ficoll-Paque
density gradient. The results show that all the selected
HSC populations have substantial clonogenic potential
and are highly non-committed. Taken together, the data
support the use of traditionally used markers to separate
HSC populations until more specific markers are found.
Conclusion
Immunomagnetic cell sorting enables fast and gentle sep-
aration of HSCs. However, the previously reported proto-
cols are not optimal for CB and result in unsatisfactory
purity and yield, indicating a need for optimization of the
procedures. With the modified protocols presented here,
over 90% pure HSC fractions can be reproducibly
obtained. This is essential for the use of specific hemat-
opoietic progenitor cell types in research and therapeutic
applications.
The single most important factor influencing engraftment
in HSC transplantation appears to be the nucleated cell
content. Even though the cell content is limited in CB and
there is no possibility to obtain an additional graft from
the same donor, the increased engraftment potential of
CB-derived HSCs makes them an appealing alternative for
HSCs from PB or BM. It remains to be seen whether the
total nucleated cell content or a population of highly pure
and specific hematopoietic progenitor cells will prove to
be more important for graft potency.
Methods
CB units
Umbilical CB was obtained from informed and consent-
ing donors at the Helsinki University Central Hospital,
Department of Obstetrics and Gynaecology. Permit to col-
lect and use donated stem cells has been obtained from
the ethics board of the Helsinki University Central Hospi-
tal (550/E8/02) and the ethics board of the Finnish Red
Cross Blood Service (40/02).
The umbilical cord was clamped according to standard
hospital procedure and CB collections were performed ex
utero. CB was collected into a sterile collection bag (Cord
Blood Collection system, Medsep Corporation, Covina,
USA) containing 25 ml of Citrate Phosphate Dextrose
solution. The collection volume varied between 45–105
ml. Some CB units were volume reduced and cryopre-
served in a BioArchive system at the Finnish Red Cross
Blood Service, Cord Blood Bank as previously described
[16,19] and some units were processed freshly within
hours from collection. Altogether, 8 cryopreserved and 12
fresh CB units were used to optimize the protocols. In
addition, 10 cryopreserved and 9 fresh CB units were used
to test the optimized protocols.
Handling of CB units
Cryopreserved CB unit was taken from the BioArchive sys-
tem and kept for 2 minutes in the gas phase of liquid
Table 1: Frequency of different types of CFU colonies within 
CD34+, CD133+, Lin- and MNC populations.
Cell type CFU-GM CFU-GEMM BFU-E CFU-E
CD34+ 58.2% 33.2% 7.2% 1.4%
CD133+ 57.4% 38.3% 4.3% 0.0%
Lin- 43.8% 26.3% 27.3% 2.6%
MNC 37.8% 41.3% 15.4% 5.5%BMC Cell Biology 2006, 7:30 http://www.biomedcentral.com/1471-2121/7/30
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nitrogen, 3–5 minutes at room temperature and then in
37°C water bath until completely thawed. CB was trans-
ferred from the freezing bag into 50 ml tubes containing
10 ml of freezing solution: 2.5% albumin (Finnish Red
Cross, Blood Service, Helsinki, Finland), 50% NaCl (Bax-
ter Healthcare) and 50% Gentran40 (Baxter Healthcare).
Cells were pelleted by centrifugation at 600 × g for 10
minutes and the supernatant was discarded. When cell
aggregation occurred, the cell pellet was resuspended in
200 µl of 1 mg/ml DNaseI (Sigma-Aldrich, Steinheim,
Germany). Cells were then suspended carefully in 100 ml
of phosphate-buffered saline (PBS, pH 7.4) supplemented
with 0.6% ACD/A. Fresh CB was diluted 1:4 with PBS sup-
plemented with 2 mM EDTA, to reduce the size and
number of cell aggregates and to give better lymphocyte
yield in density gradient centrifugation.
MNCs were isolated by density gradient using 15 ml of
Ficoll-Paque reagent (Amersham Biociences, Piscataway,
USA) and 35 ml of diluted CB. The two-phase system was
centrifuged at 400 × g for 40 minutes. MNCs, collected
from the interface of the two phases, were washed twice
with PBS. MNC counting was performed by automatic cell
counter Sysmex K-1000 (Sysmex Corporation, Kobe,
Japan).
Separation of CD34+/CD133+ cells
CD34+ and CD133+ cells were enriched through positive
selection using MiniMACS or MidiMACS separation sys-
tems (Miltenyi Biotec). For the labeling of CD34+ cells,
Direct CD34 Progenitor Cell Isolation Kit was used,
whereas CD133+ cells were labeled using the CD133 Cell
Isolation Kit. 100 µl of FcR Blocking Reagent, to inhibit
unspecific or Fc-receptor mediated binding, and 100 µl of
CD34/CD133 MicroBeads for magnetic labeling of cells
were added per 108 cells, as per manufacturer's recom-
mendations.
MS or LS MACS affinity columns were used depending on
the number of MNCs. MS column was used for up to 2 ×
108 MNCs, and LS column was used for 2 × 108 to 2 × 109
of MNCs. Labeled cell suspension was subjected to immu-
nomagnetic separation where magnetically labeled cells
retain in the column while the unlabeled cells pass
through the column. After several washes, the column was
removed from the magnet and the retained CD34+ or
CD133+ cells were eluted with 1–5 ml of PBS supple-
mented with 0.5% bovine serum albumin and 2 mM
EDTA. CD34+ and CD133+ cells were subjected to one or
two rounds of separation and their negative counterparts
were collected for control purposes. In the two-column
system, an additional labeling step between the column
separations was tested, using 25 µl of both FcR Blocking
Reagent and MicroBeads. The optimum purity and yield
was obtained when using the additional labeling step in
connection with the two-column system.
Separation of Lin- cells
To enrich progenitor cells, lineage committed cells were
depleted. MNCs (8 × 107/ml) were labeled with Progeni-
tor Enrichment Cocktail containing antibodies against
CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66b
and Glycophorin A (StemCell Technologies, Vancouver,
Canada) at room temperature for 15 minutes. Subse-
quently, the cell suspension was incubated with magnetic
iron particles at room temperature for 15 minutes. Vary-
ing concentrations of StemSep Progenitor Enrichment
Cocktail (100 µl/ml, 75 µl/ml, and 50 µl/ml) and mag-
netic iron particles (60 µl/m, 45 µl/ml, and 30 µl/ml)
were tested. Cell suspension was loaded into MACS LD
column (Miltenyi Biotec) and unlabeled cells passing
through the column were collected (Lin- fraction). The
column was then washed twice with 1 ml of buffer and the
remaining Lin+ cells were collected for control purposes.
The conditions resulting in optimal separation of Lin-
cells were 100 µl of Progenitor Enrichment Cocktail and
60 µl of magnetic iron particles per 8 × 107/ml MNCs, as
recommended by the manufacturer.
Purity
To determine the purity of CD34+/- and CD133+/- cell
fractions, 1 × 105 cells were labeled with fluorescein iso-
thiocyanate (FITC)-conjugated anti-CD45 (clone 2D1,
Becton Dickinson, Franklin Lakes, USA) and phycoeryth-
rin (PE)-conjugated anti-CD34 (clone 345802 Becton
Dickinson) or PE-conjugated anti-CD133 (clone 293C3,
Miltenyi Biotec) monoclonal antibodies at 4°C for 15
minutes. Lin-/+ cells were labeled with PE-conjugated
anti-mouse immunoglobulin specific polyclonal anti-
body (BD Biosciences, San Jose, USA). Platelets were
detected with PE-conjugated anti-CD41a monoclonal
antibody (BD Biosciences, San Jose, USA). Isotype-identi-
cal monoclonal antibodies served as controls. Labeled
cells were analyzed using Becton Dickinson FACSCali-
bur™ with a 488 nm blue argon laser. Fluorescence was
measured using 530/30 nm (FITC) and 585/42 nm (PE)
bandpass filters. Data were analyzed using the Pro-
COUNT™ software (BD Biosciences) or Windows Multi-
ple Document Interface for Flow Cytometry, WinMDI
version 2.8 [23]. CD34+, CD133+ and Lin- cell popula-
tions were defined by first gating on forward and side scat-
ter properties excluding platelets and debris. Subsequent
gates were set to exclude >99% of control cells labeled
with isotype-specific antibody.
Colony forming unit assay
MNCs (1 × 105) and enriched HSCs (2 × 103) suspended
in 300 µl Iscove's Modified Dulbecco's Medium supple-
mented with 2% fetal bovine serum (Gibco/Invitrogen,BMC Cell Biology 2006, 7:30 http://www.biomedcentral.com/1471-2121/7/30
Page 9 of 10
(page number not for citation purposes)
Paisley, United Kingdom) were mixed vigorously with 3
ml of MethoCult GF H4434 containing recombinant
cytokines and erythropoietin (StemCell Technologies).
The cells in MethoCult medium were plated in duplicate
into sterile 35 mm petri dishes, and colonies were scored
according to their morphological characteristics by light
microscopy after a 14-day culture. Cell culture and colony
scoring were performed according to accredited method-
ology (Finnish Cord Blood Bank, Finnish Red Cross
Blood Service, Helsinki, Finland) following international
standards [24,25]. The CFU assay was performed in tripli-
cate for each cell type (CD34+, CD133+, Lin- and MNC).
Statistical analysis
For statistical analysis of total MNC counts between cryo-
preserved and fresh CB samples, the non-parametric
Mann-Whitney test was used, as the MNC counts were not
normally distributed. The two groups, cryopreserved and
fresh CB, were considered independent as they have been
produced using different protocols. The recovery of
CD34+, CD133+ and Lin- cells between cryopreserved
and fresh CB was compared in independent samples by
the t test and equality of variances was checked by Lev-
ene's test. When the assumption of equality was not satis-
fied, as with Lin- cells, the t test for non-equal variances
was used to compensate the lack of homoscedasticity. P
values less than 0.05 were considered statistically signifi-
cant. The analyses were performed by Microsoft Excel and
SPSS 12.0.1.
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